Table S3.
Sensitivity analysis for pooled sensitivities and corresponding heterogeneities
| A | |||
|---|---|---|---|
|
| |||
| Studya | SEN (95% CI) | I2 index (%) | Pb |
|
| |||
| Porzycki et al1 | 0.91(0.87–0.94) | 0 | 0.43 |
| Yang et al2,c | 0.90 (0.85–0.94) | 0 | 0.58 |
| Yang et al2,d | 0.90 (0.85–0.93) | 0 | 0.75 |
| Gao et al3 | 0.92 (0.88–0.95) | 0 | 0.58 |
| Huang et al4 | 0.92 (0.87–0.95) | 0 | 0.61 |
| Kotb et al5 | 0.91(0.88–0.94) | 0 | 0.434 |
|
| |||
| B | |||
|
| |||
| Studya | SEN (95% CI) | I2 index (%) | Pb |
|
| |||
| Zhu et al6 | 0.73(0.66–0.79) | 78.3 | 0.01 |
| Huang et al7 | 0.72 (0.66–0.76) | 71.3 | 0.03 |
| Chen et al8,c | 0.71 (0.65–0.76) | 68.5 | 0.04 |
| Chen et al8,d | 0.76 (0.70–0.80) | 33.4 | 0.22 |
Notes: (A) miR-21, (B) miR-30c.
a
Given named study is omitted.
b
P-value of the Cochrane-Q test.
c
Control group consisted of patients with benign prostate disease.
d
Control group consisted of healthy people.